- Home
- EVRG vs INSM Comparison
EVRG vs INSM Comparison
Compare EVRG & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EVRG | INSM |
|---|---|---|
| Founded | 2017 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.0B | 22.4B |
| IPO Year | 2017 | 2000 |
Fundamental Metrics
Financial Performance| Metric | EVRG | INSM |
|---|---|---|
| Price | $81.15 | $100.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 24 |
| Target Price | $91.36 | ★ $197.74 |
| AVG Volume (30 Days) | 2.0M | ★ 2.4M |
| Earning Date | 11-05-2026 | 10-29-2026 |
| Dividend Yield | ★ 3.45% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $5,961,600,000.00 | N/A |
| Revenue This Year | $5.46 | $197.18 |
| Revenue Next Year | $5.83 | $59.72 |
| P/E Ratio | $125.81 | ★ N/A |
| Revenue Growth | ★ 1.95 | N/A |
| 52 Week Low | $71.41 | $90.39 |
| 52 Week High | $88.62 | $212.75 |
Technical Indicators
Market Signals| Indicator | EVRG | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 57.78 | 29.59 |
| Support Level | $80.05 | $97.66 |
| Resistance Level | $83.90 | $119.54 |
| Average True Range (ATR) | 1.03 | 4.56 |
| MACD | 0.39 | -1.92 |
| Stochastic Oscillator | 100.00 | 14.65 |
Price Performance
Historical ComparisonAbout EVRG Evergy Inc.
Evergy is a regulated electric utility serving eastern Kansas and western Missouri. Major operating subsidiaries include Evergy Metro, Evergy Kansas Central, Evergy Missouri West, and Evergy Transmission. The utility has a combined rate base of more than $20 billion, about half in Kansas and the rest split between Missouri and interstate transmission. Evergy is one of the largest wind energy suppliers in the US.
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.